Take­da ex­plores com­pu­ta­tion­al chem­istry leads from Schrödinger in $170M-plus pact; Aeter­na Zen­taris boots CEO, con­sid­ers op­tions

→ Take­da is in­clud­ing an in sil­i­co dis­cov­ery pact with Schrödinger to aug­ment its re­struc­tured R&D op­er­a­tions. Schrödinger stands to earn up to $170 mil­lion per pro­gram in the deal, look­ing to de­sign new chem­i­cal en­ti­ties that the phar­ma com­pa­ny can take in­to the clin­ic. “In this case, Schrödinger is tak­ing the lead role in dis­cov­ery, with Take­da play­ing a sup­port­ing role, lever­ag­ing its in-house struc­tur­al bi­ol­o­gy team and ther­a­peu­tic area ex­per­tise,” says Take­da’s Stephen Hitch­cock.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.